Antigenic targets of CAR T Cell Therapy. A retrospective view on clinical trials

Experimental Cell Research
Fatemeh ArabiMahmood Naderi

Abstract

Chimeric antigen receptor (CAR) T cell therapy is anticipated to be increasingly implemented in the context of cancer treatment after two current FDA approval of anti-CD19 CAR-T cells (Kymriah™ & Yescarta™). The success of CD19 is mainly attributable to the proper selection of the antigen, CD19, as the target of the disease, highlighting the importance of target selection for other CAR therapies. Therefore, here we performed a global analysis of targets that are the prime focus for various CAR T cell therapies in human clinical trials.

Citations

Jul 6, 2019·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Sasan GhaffariNaser Ahmadbeigi
Aug 24, 2019·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Ian W FolkertMalay Haldar
Jan 18, 2019·Experimental and Therapeutic Medicine·Lin YeXiaohong Fan
Jan 10, 2021·International Journal of Molecular Sciences·Guendalina FroechlichNicola Zambrano
Jul 4, 2021·Cellular Immunology·Seyed Mostafa MonzaviSamad Muhammadnejad
Jul 7, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Vahid MansouriNima Rezaei
Jan 5, 2022·Annals of the New York Academy of Sciences·Mohadeseh Mirzaee GodarzeeMajid Sadeghizadeh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.